Just a few months after raising $200 million in third-round financing, immunology specialist Zenas ... acceleration in the number of biotech companies seeking public listings after a two-year ...

AbbVie in partnership with the University of Toronto's SpinUp, are pleased to announce Neuropeutics Inc as the recipient of the AbbVie Biotech Innovators Award, a national prize to help foster ...

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, today announced the appointment of Maude Tessier, Ph.D., as ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

Bio Usawa, a private biotech company focused on boosting drug access in Africa, inked a deal with cleanroom and laboratory ...

Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...

Story April 9 - Vincerx Pharma: With two attempts to merge with other companies having ... In a shift to focus on immunology and inflammation indications, the biotech is halting further ...

The antibody market has become a cornerstone of modern biotechnology and pharmaceutical industries, underpinning a vast array of diagnostic and therapeutic applications. Antibodies, which are proteins ...

In summary, although deal volume is down, there are fewer but larger deal sizes. Life sciences companies that can demonstrate ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...